A study suggested the possibility that combined immunohistochemical expression of EZH2, H3K4me2, and H3K27me3 might identify cancer cells with potential stem cell properties; another relevant data that many epigenetic changes are pharmacologically reversible (Kampilafkos et al., 2015; Mahmoud et al., 2016). Here, EZH2 is linked to cancer.